AI Article Synopsis
- On November 7, 1923, J.J.R. Macleod announced he would share his Nobel Prize with J.B. Collip after F.G. Banting shared his half with C.H. Best.
- Macleod humbly described his role in the discovery of insulin as merely being an "impresario," but his expertise and leadership were critical to the development of insulin as an effective diabetes treatment.
- The consensus is that while his humility is noted, Macleod's significant contributions in research and management were essential for the success of the insulin project.
Article Abstract
On 7 November 1923, when J.J.R. Macleod announced that he would split his half of the Nobel Prize with J.B. Collip, following F.G. Banting splitting his half of the prize with C.H. Best, a reporter asked Macleod to assess his share in the discovery of insulin. "Oh, I was only the impresario - the managing director," he replied. Whether Macleod deserved the recognition with Banting of the Nobel Committee for the discovery of insulin, it is certainly clear that the discovery, and especially its efficient development into a remarkably effective diabetes treatment, would not have happened without Macleod's knowledge and laboratory research experience. Nor would it have happened without his leadership and, especially, without his acumen as the managing director, or impresario, of the insulin enterprise.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3138/cjhh.616-102022 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
'I Was Only the Impresario - the Managing Director': J.J.R. Macleod and the Pragmatics of the Discovery and Development of Insulin.
Can J Health Hist
September 2023
Dalla Lana School of Public Health, University of Toronto, Toronto, Canada.
Article Synopsis
- On November 7, 1923, J.J.R. Macleod announced he would share his Nobel Prize with J.B. Collip after F.G. Banting shared his half with C.H. Best.
- Macleod humbly described his role in the discovery of insulin as merely being an "impresario," but his expertise and leadership were critical to the development of insulin as an effective diabetes treatment.
- The consensus is that while his humility is noted, Macleod's significant contributions in research and management were essential for the success of the insulin project.
Boston Scientific founder John Abele has been party to his share of groundbreaking innovations over the years. But the revolutionary advances in medical science that these breakthroughs brought about were not the efforts of one firm alone, let alone one inventor. Abele tells two fascinating stories of collaboration--one about Jack Whitehead's upending of hospitals' blood and urine testing procedures and the other about Andreas Gruentzig's success in bringing balloon catheterization into the cardiology mainstream.
View Article and Find Full Text PDFWho is really in control of skin immunity under physiological circumstances - lymphocytes, dendritic cells or keratinocytes?
Exp Dermatol
November 2006
Department of Dermatology, University Hospital Schleswig-Holstein, Campus Kiel, University of Kiel, D-24105 Kiel, Germany.
Our views of the skin immunity theatre are undergoing constant change. These not only reflect paradigm shifts in general immunology and skin biology, but also have profound clinical implications, which call for strategic changes in dermatological therapy. Nowhere can this be witnessed at a greater level of instructiveness and fascination than when addressing the question posed by this new Controversies feature.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!